Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814733 · ClinicalTrials.gov registry record · Phase 1
Assessment of Effect of Rapastinel on Driving Performance
A Phase 1 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03814733 is a Phase 1 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 107 participants.
The verdict
NCT03814733, a Phase 1 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.
Interventions
- DRUG Ketamine
- DRUG Alprazolam
- DRUG Rapastinel
- DRUG Rapastinel Matched Placebo
- DRUG Alprazolam Matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03814733
The ClinicalTrials.gov registry entry for NCT03814733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ketamine is the first listed.
NCT03814733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03814733 about?
NCT03814733 is a clinical study titled "Assessment of Effect of Rapastinel on Driving Performance". Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy partici...
What is the current status of trial NCT03814733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2018-11-05. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT03814733?
The interventions under investigation include: Ketamine (DRUG), Alprazolam (DRUG), Rapastinel (DRUG), Rapastinel Matched Placebo (DRUG), Alprazolam Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT03814733?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.